Get started
Author

Joshua C. Horan

Observed names: Horan, J.C., J. C. Horan, J.C. Horan, Joshua Horan
ORCID: 0000-0003-4700-5215
Observed ORCID: 0000-0003-4700-5215
OpenAlex ID: A5022400371
The Practical Synthesis of a Novel and Highly Potent Analogue of Bryostatin
2002 · Paul A. Wender, Jeremy L. Baryza, et al. · Journal of the American Chemical Society · 156
The Clinically-tested S1P Receptor Agonists, FTY720 and BAF312, Demonstrate Subtype-Specific Bradycardia (S1P1) and Hypertension (S1P3) in Rat
2012 · Ryan M. Fryer, Akalushi Muthukumarana, et al. · PLoS ONE · 81
PDF
NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations
2024 · Jessica J. Lin, Joshua C. Horan, et al. · Cancer Discovery · 69
NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations
2022 · Alexander Drilon, Joshua C. Horan, et al. · Cancer Discovery · 55
Function Oriented Synthesis: The Design, Synthesis, PKC Binding and Translocation Activity of a New Bryostatin Analog
2004 · Paul Wender, Jeremy Baryza, et al. · Current Drug Discovery Technologies · 53
Inspirations from nature. New reactions, new therapeutic leads, and new drug delivery systems
2003 · P. A. Wender, J. L. Baryza, et al. · Pure and Applied Chemistry · 45
PDF
Total Synthesis and Initial Biological Evaluation of New B-Ring-Modified Bryostatin Analogs
2006 · Paul A. Wender, Joshua C. Horan, et al. · Organic Letters · 43
Synthesis and PKC Binding of a New Class of A-Ring Diversifiable Bryostatin Analogues Utilizing a Double Asymmetric Hydrogenation and Cross-Coupling Strategy
2006 · Paul A. Wender, Joshua C. Horan · Organic Letters · 33
Abstract 1468: NUV-655 (NVL-655) is a selective, brain-penetrant ALK inhibitor with antitumor activity against the lorlatinib-resistant G1202R/L1196M compound mutation
2021 · Henry E. Pelish, Anupong Tangpeerachaikul, et al. · Cancer Research · 26
Role of the A-Ring of Bryostatin Analogues in PKC Binding: Synthesis and Initial Biological Evaluation of New A-Ring-Modified Bryologs
2005 · Paul A. Wender, Michael O. Clarke, et al. · Organic Letters · 24
Zidesamtinib Selective Targeting of Diverse ROS1 Drug-Resistant Mutations
2025 · Anupong Tangpeerachaikul, Scot Mente, et al. · Molecular Cancer Therapeutics · 10
PDF
Piperazinyl-oxadiazoles as selective sphingosine-1-phosphate receptor agonists
2014 · Joshua C. Horan, Sulagna Sanyal, et al. · Bioorganic & Medicinal Chemistry Letters · 6
Abstract 1979: Preclinical characterization of NVL-330, a selective and brain penetrant HER2 tyrosine kinase inhibitor with broad activity on HER2 oncogenic alterations
2024 · Yuting Sun, Kristin L. Andrews, et al. · Cancer Research · 4
Abstract P244: NVL-655 exhibits antitumor activity in lorlatinib-resistant and intracranial models of ALK-rearranged NSCLC
2021 · Anupong Tangpeerachaikul, Amit Deshpande, et al. · Molecular Cancer Therapeutics · 4
Abstract 1465: NUV-520 (NVL-520) is a brain-penetrant and highly selective ROS1 inhibitor with antitumor activity against the G2032R solvent front mutation
2021 · Henry E. Pelish, Anupong Tangpeerachaikul, et al. · Cancer Research · 4
Beyond Natural Products: Synthetic Analogues of Bryostatin 1
2006 · Paul A. Wender, Jeremy L. Baryza, et al. · Wiley eBooks · 3
Abstract LB366: Zidesamtinib has differentiated preclinical brain penetrance and intracranial activity compared to other ROS1 inhibitors
2026 · Anupong Tangpeerachaikul, Joshua C. Horan, et al. · Cancer Research · 1
NVL-330 is a selective, brain-penetrant inhibitor of oncogenic HER2 exon 20 insertion mutations in preclinical models
2022 · K.L. Andrews, Y. Sun, et al. · European Journal of Cancer · 1
PDF
Abstract P247: Evaluating TRKB activity of novel preclinical brain-penetrant ROS1 and ALK inhibitors
2021 · Anupong Tangpeerachaikul, Joshua C. Horan, et al. · Molecular Cancer Therapeutics · 1
Supplementary Figures S1-S16 from NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations
2025 · Alexander Drilon, Joshua C. Horan, et al.
PDF
Abstract B057: Preclinical intracranial activity of NVL-330, a selective HER2 tyrosine kinase inhibitor
2025 · Yuting Sun, Kristin L. Andrews, et al. · Molecular Cancer Therapeutics
Supplementary Table S6 from Zidesamtinib Selective Targeting of Diverse ROS1 Drug-Resistant Mutations
2025 · Anupong Tangpeerachaikul, Scot Mente, et al.
Supplementary Table S7 from Zidesamtinib Selective Targeting of Diverse ROS1 Drug-Resistant Mutations
2025 · Anupong Tangpeerachaikul, Scot Mente, et al.
Supplementary Figure S7 from Zidesamtinib Selective Targeting of Diverse ROS1 Drug-Resistant Mutations
2025 · Anupong Tangpeerachaikul, Scot Mente, et al.
Data from Zidesamtinib Selective Targeting of Diverse ROS1 Drug-Resistant Mutations
2025 · Anupong Tangpeerachaikul, Scot Mente, et al.
Works count: 52
Citation count: 619
H-index: 10
I10-index: 11
Year
Topic
Type